4D Molecular Therapeutics

Forecast & Rating11 analysts currently cover 4D Molecular Therapeutics, with about 81.8% giving a positive rating — meaning they expect the stock to rise. The average price target is $28.22, about 180.3% upside from the current price of $10.07. Price targets range from $17.00 to $36.00 — a wide spread, showing clear disagreement over just how much 4D Molecular Therapeutics can rise. Historically, about 29.9% of past price targets were eventually met, which adds credibility. For you, this means most professionals who study 4D Molecular Therapeutics closely still see room for the stock to rise. Data as of Jul 21, 2026; for reference only and not investment advice.